Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine with Epinephrine vs Sham in Endoscopic Sinus Surgery
NCT06456255Phase 3Recruiting
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine and epinephrine in paranasal sinus disease (2 arms). Primary endpoint: Boezzart Bleeding Score. Started Nov 2024; status: recruiting.
02
Drugs
bupivacaineepinephrine
03
Conditions
paranasal sinus disease
Beyond the preview
Go deeper on NCT06456255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456255.